Spyre Therapeutics Inc. (SYRE), which made significant advancements in its next-generation inflammatory bowel disease pipeline in 2024, has two clinical trial data releases planned for this year.
The company's lead drug candidate is SPY001, a novel, subcutaneous extended half-life monoclonal antibody targeting a4ß7 for the potential treatment of inflammatory bowel disease. Integrin a4ß7 plays a crucial role in the pathogenesis of inflammatory bowel disease.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.